Literature DB >> 16313499

Short- and long-term effects of melatonin on myocardial post-ischemic recovery.

Amanda Lochner1, Sonia Genade, Ashraf Davids, Kirsti Ytrehus, Johan A Moolman.   

Abstract

Melatonin, the chief secretory product of the pineal gland, has been shown to protect the heart against ischemia-reperfusion injury. This was attributed to its free radical scavenging and broad-spectrum antioxidant properties. The possibility that melatonin may act via its receptor and intracellular signaling, has not yet been addressed in this regard. In all previous studies, only the acute effects of melatonin on the heart, were evaluated. The aims of the present study were to: (i) compare the acute and long-term effects of melatonin on infarct size and functional recovery of the ischemic heart, and (ii) evaluate the role of the melatonin receptor in cardioprotection. For evaluation of the short-term effects of melatonin on contractile recovery and infarct size, the isolated perfused working rat heart was subjected to 20 min global ischemia or 35 min regional ischemia respectively, and melatonin (25-50 microm) administered either before and during reperfusion, or before ischemia or during reperfusion after ischemia. The melatonin receptor was manipulated using luzindole and N-acetyltryptamine. The long-term effects of melatonin were evaluated 24 hr after melatonin administration (2.5 or 5.0 mg/kg, i.p.) or after oral administration for 7 days (20 or 40 microg/mL). Infarct size and mechanical recovery during reperfusion of the working heart were used as endpoints. Melatonin (50 microm), when administered either before and during reperfusion after ischemia or during reperfusion only, significantly improved cardiac output and work performance and reduced infarct size compared with untreated controls. Luzindole (5 microm), a melatonin receptor antagonist, abolished these cardioprotective effects. Long-term administration of melatonin (i.p. or orally for 7 days) caused a significant reduction in infarct size of hearts subjected to 35 min regional ischemia. The cardioprotection persisted for 2-4 days after discontinuation of treatment. In summary, the results obtained suggest that melatonin induces short- as well as long-term protection and that the melatonin receptor is also involved in its cardioprotective actions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16313499     DOI: 10.1111/j.1600-079X.2005.00280.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  14 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

Review 2.  Hepatoprotective actions of melatonin: possible mediation by melatonin receptors.

Authors:  Alexander M Mathes
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Prevention of ischemia/reperfusion-induced cardiac apoptosis and injury by melatonin is independent of glutathione peroxdiase 1.

Authors:  Zhongyi Chen; Chu C Chua; Jinping Gao; Kao-Wei Chua; Ye-Shih Ho; Ronald C Hamdy; Balvin H L Chua
Journal:  J Pineal Res       Date:  2008-12-11       Impact factor: 13.007

4.  Melatonin increases the regularity of cardiac rhythmicity in the Drosophila heart in both wild-type and strains bearing pathogenic mutations.

Authors:  Tricia VanKirk; Evelyn Powers; Harold B Dowse
Journal:  J Comp Physiol B       Date:  2016-07-22       Impact factor: 2.200

Review 5.  Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?

Authors:  Puneet Kaur Randhawa; Manish Kumar Gupta
Journal:  Eur J Pharmacol       Date:  2020-08-26       Impact factor: 4.432

6.  Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial.

Authors:  Sarah Ekeloef; Natalie Halladin; Siv Fonnes; Svend Eggert Jensen; Tomas Zaremba; Jacob Rosenberg; Grete Jonsson; Jens Aarøe; Lærke Smidt Gasbjerg; Mette Marie Rosenkilde; Ismail Gögenur
Journal:  J Cardiovasc Transl Res       Date:  2017-10-12       Impact factor: 4.132

Review 7.  Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2018-08-13       Impact factor: 9.261

Review 8.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

9.  Effect of Melatonin on Cardiac Injury after Primary Percutaneous Coronary Intervention: a Randomized Controlled Trial.

Authors:  Padideh Ghaeli; Shaghayegh Vejdani; Atefeh Ariamanesh; Azita Hajhossein Talasaz
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

Review 10.  Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?

Authors:  Zukiswa Jiki; Sandrine Lecour; Frederic Nduhirabandi
Journal:  Front Physiol       Date:  2018-05-17       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.